The Neurosafe PROOF trail results were published yesterday in the Lancet.
Effect of NeuroSAFE-guided RARP versus standard RARP on erectile function and urinary continence in patients with localised prostate cancer (NeuroSAFE PROOF): a multicentre, patient-blinded, randomised, controlled phase 3 trial
This trial took men with localised prostate cancer who were eligible for the Neurosafe procedure. They were randomised to have either Neurosafe or standard RALP, but they have never been told which they had. The trial compares how the two arms have done.
Erectile function was significantly better on average in the Neurosafe group at 12 months. Continence was also better at 3 months, but no difference by 6 months. (I haven't read enough of it yet to know if that might be a difference in using Retzius Sparing or not.)
The Neurosafe group had a larger percentage of recurrence and further treatment required although that's not mentioned in the summary for some reason. It should be noted that not enough time has passed for a real judgement on the final percentages of these figures and it could be that over the longer term, the difference might reduce or increase.
The trial hopes to report again in the future too, when more time has passed and further data collected. (Hence the reason the trial has not been unblinded.)